KAYEXALATE (sodium polystyrene sulfonate) by ANI Pharmaceuticals is potassium ion exchange activity [moa]. First approved in 1958.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
KAYEXALATE is a sodium polystyrene sulfonate powder administered orally or rectally that treats hyperkalemia by exchanging sodium ions for potassium ions in the gastrointestinal tract. It is indicated for patients with elevated serum potassium levels, particularly those with chronic kidney disease or acute kidney injury. The ion-exchange mechanism reduces serum potassium concentration by promoting fecal excretion.
As LOE approaches, brand team focus shifts from growth to market defense and lifecycle extension strategies; team sizes may stabilize or consolidate.
Potassium Ion Exchange Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
KAYEXALATE career opportunities are limited due to zero linked job postings and mature market position under LOE. Positions that do exist focus on brand defense, managed care negotiations, and maintaining market share against competitors and generics rather than growth or innovation.
Worked on KAYEXALATE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo